Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseasesResponse to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677-1683.

× No keyword cloud information.

17 in total

Review 1. Novel Therapeutics in Psoriatic Arthritis. What Is in the Pipeline?

Authors: Ofir Elalouf; Vinod Chandran
Journal: Curr Rheumatol Rep Date: 2018-05-30 Impact factor: 4.592

2. Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet's disease after switching from infliximab originator.

Authors: Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Emanuele Cassarà; Olga Kaloudi
Journal: Eur J Rheumatol Date: 2017-10-25

3. Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study.

Authors: E M H Schmitz; S Benoy-De Keuster; A J L Meier; V Scharnhorst; R A M Traksel; M A C Broeren; L J J Derijks
Journal: Clin Rheumatol Date: 2017-06-07 Impact factor: 2.980

4. The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases.

Authors: Cosimo Bruni; Stefano Gentileschi; Giovanni Pacini; Caterina Baldi; Marco Capassoni; Lorenzo Tofani; Marco Bardelli; Laura Cometi; Luca Cantarini; Francesca Nacci; Michele Vietri; Francesca Bartoli; Ginevra Fiori; Bruno Frediani; Marco Matucci-Cerinic
Journal: Ther Adv Musculoskelet Dis Date: 2020-10-13 Impact factor: 5.346

5. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.

Authors: Maurizio Benucci; Francesca Li Gobbi; Francesca Bandinelli; Arianna Damiani; Maria Infantino; Valentina Grossi; Mariangela Manfredi; Simone Parisi; Enrico Fusaro; Alberto Batticciotto; Piercarlo Sarzi-Puttini; Fabiola Atzeni; Francesca Meacci
Journal: Immunol Res Date: 2017-02 Impact factor: 2.829

Review 6. Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.

Authors: Robert Moots; Valderilio Azevedo; Javier L Coindreau; Thomas Dörner; Ehab Mahgoub; Eduardo Mysler; Morton Scheinberg; Lisa Marshall
Journal: Curr Rheumatol Rep Date: 2017-06 Impact factor: 4.592

Review 7. A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.

Authors: Andrea Becciolini; Maria Gabriella Raimondo; Chiara Crotti; Elena Agape; Martina Biggioggero; Ennio Giulio Favalli
Journal: Drug Des Devel Ther Date: 2017-06-28 Impact factor: 4.162

Review 8. Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.

Authors: Ross A McKinnon; Matthew Cook; Winston Liauw; Mona Marabani; Ian C Marschner; Nicolle H Packer; Johannes B Prins
Journal: BioDrugs Date: 2018-02 Impact factor: 5.807

9. Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies.

Authors: Syed Numan; Freddy Faccin
Journal: Adv Ther Date: 2018-08-06 Impact factor: 3.845

Review 10. The biosimilars journey: current status and ongoing challenges.

Authors: Igor Age Kos; Valderílio Feijó Azevedo; Daniel Egg Neto; Sérgio Cândido Kowalski
Journal: Drugs Context Date: 2018-10-01